化合物 GW0742|T6524|TargetMol

2篇文獻(xiàn)

價(jià)格	￥313	￥478	￥788
包裝	2mg	5mg	10mg

最小起訂量	2mg
發(fā)貨地	上海
更新日期	2026-05-08

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:化合物 GW0742	英文名稱:GW0742
CAS:317318-84-6	品牌: TargetMol
產(chǎn)地: 美國	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
純度規(guī)格: 99.85%	產(chǎn)品類別: 抑制劑
貨號(hào): T001\|T6524

Product Introduction

Bioactivity

名稱	GW0742
描述	GW0742 (GW610742) is an effective and specific PPARδ agonist (EC50: 1 nM/1.1 μM/2 μM, for human PPARδ/α/γ).
細(xì)胞實(shí)驗(yàn)	N/TERT-1 keratinocytes are seeded onto 6-well tissue culture dishes at 3×104 cells per well in Ker-SFM. Twenty-four hours later, cell number is measured with a Z1 coulter particle counter to determine plating efficiency (Day 0). For the remaining cells, medium is changed to Ker-SFM/DF-K, and cells are treated in triplicate with 0.1% DMSO, 0.1 μM or 1 μM GW0742. Cell number is determined at daily intervals, and the remaining cells are retreated with fresh media and treatment each day for up to 6 days.(Only for Reference)
體外活性	GW0742 shows activity aganist hPPARα, hPPARγ and hPPARδ with EC50 of 1.1 μM, 2 μM and 1 nM, respectively, in cell based transactivation assay. [1] GW0742 (0.2 μM and 1 μM) significant increases in reporter activity of PPARβ/δ in N/TERT-1 keratinocytes. GW0742 (1 μM) results in significant inhibition in the average number of N/TERT-1 keratinocytes. GW0742 (1 μM) results in an increase in the number of cells in the G1 phase and a decrease in the number of cells in the S phase. GW0742 (1 μM) causes a significant increase in the mRNA encoding ADRP, a known PPARβ/δ target gene, in N/TERT-1 keratinocytes as well as mouse primary keratinocytes. GW0742 (1 μM) results in significantly reduced phosphorylation of retinoblastoma (Rb) and a significantly lower level of p42/44 ERK in N/TERT-1 cells. GW0742 (1 μM) leads to an increase in the mRNA encoding a number of known markers of terminal differentiation including TG-I, SPR1A, K10 and involucrin. [2] GW0742 at 100 μM produces a significant reduction in low-KCl-induced neuronal cell death in cerebellar granule neurons. GW0742 at 100 μM induces a pronounced increase in cell death as measured by LDH release after 48 hr of incubation. GW0742 at 100 μM produces a pronounced increase in c-Jun expression at 6 hours in cerebellar granule neuron cultures. GW0742 at 100 μM increases PPARα-mediated transactivation dependent on the presence of 1.5% BSA in MCF-7 cells. [3]
體內(nèi)活性	GW0742-treatment (0.3 mg/Kg, 10 % DMSO, i.p.) has therapeutic effects on pulmonary damage, decreasing many inflammatory and apoptotic parameters detected by measurement of 1) cytokine production; 2) leukocyte accumulation, indirectly measured as decrease of myeloperoxidase (MPO) activity; 3) IkBα degradation and NF-kB nuclear translocation; 4) ERK phosphorylation; 5) stress oxidative by NO formation due to iNOS expression; 6) nitrotyrosine and PAR localization; 7) the degree of apoptosis, evaluated by Bax and Bcl-2 balance, FAS ligand expression and TUNEL staining. Taken together, GW0742 reduces the lung injury and inflammation due to the intratracheal BLEO--instillation in mice.
存儲(chǔ)條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
溶解度	10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (21.21 mM), Suspension. 10% DMSO+90% Saline : < 10 mg/mL (21.21 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. DMSO : 250 mg/mL (530.23 mM), Sonication is recommended.
關(guān)鍵字	PPARδ \| PPARγ \| PPARα \| PPAR \| Peroxisome proliferator-activated receptors \| Inhibitor \| inhibit \| GW-610742 \| GW-0742 \| GW0742 \| GW 610742 \| GW 0742
相關(guān)產(chǎn)品	Magnesium acetate tetrahydrate \| Icariin \| Daidzein \| PHYTOL \| Rosiglitazone \| Fenofibrate \| Retinoic acid \| 2,3-Butanediol \| Cloxiquine \| NPC 15199 \| Naringenin \| Maltitol
相關(guān)庫	經(jīng)典已知活性庫 \| 抗癌活性化合物庫 \| 已知活性化合物庫 \| 轉(zhuǎn)錄因子庫 \| 抗胰腺癌化合物庫 \| 抗衰老化合物庫 \| 臨床前化合物庫 \| 抗肥胖化合物庫 \| DNA 損傷和修復(fù)分子庫 \| 免疫/炎癥分子化合物庫 \| 神經(jīng)退行性疾病化合物庫 \| 鐵死亡化合物庫

關(guān)鍵字： GW610742;[4-[[[2-[3-氟-4-(三氟甲基)苯基]-4-甲基-5-噻唑基]甲基]硫代]-2-甲基苯氧基]乙酸;TargetMol

公司簡(jiǎn)介

上海陶術(shù)生物科技有限公司為美國Target Molecule Corp. ( Target Mol ) 在上海建立的全資子公司。我們與美國波士頓、德國慕尼黑的同事一起，為北美、歐洲和亞洲從事藥物研發(fā)和生物學(xué)研究的科學(xué)家提供優(yōu)質(zhì)的產(chǎn)品和專業(yè)的服務(wù)。公司下設(shè)篩選事業(yè)部，化學(xué)事業(yè)部，生物事業(yè)部和新材料部。從虛擬篩選到實(shí)體化合物分子供應(yīng)；從商業(yè)化產(chǎn)品銷售到個(gè)性化定制合成；從對(duì)明確靶點(diǎn)的分子篩選到對(duì)明確分子的多靶點(diǎn)篩選，從高通量篩選到化學(xué)結(jié)構(gòu)優(yōu)化，我們都可以滿足您的科研用品及技術(shù)服務(wù)的需求。經(jīng)過在中國市場(chǎng)五年的精心耕耘，我們已成為篩選化合物領(lǐng)域優(yōu)秀的供應(yīng)商，為超過五百家學(xué)校和各類企業(yè)提供了品質(zhì)卓越的小分子化合物和藥物篩

成立日期	2013-04-18 （14年）	注冊(cè)資本	566.2651萬人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營行業(yè)	化學(xué)試劑,生物活性小分子	經(jīng)營模式	貿(mào)易,試劑,定制,服務(wù)

TargetMol中國（陶術(shù)生物）

VIP 14年

公司成立：14年
注冊(cè)資本：566.2651萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營產(chǎn)品：小分子抑制劑，藥物篩選化合物庫，天然產(chǎn)物，活性分子化合物等
公司地址：上海市閘北區(qū)江場(chǎng)三路28號(hào)4樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

靶點(diǎn)化合物庫

￥5000

篩選化合物庫

￥100000

化合物 CI994|T1888

￥198